Literature DB >> 7511598

Accessibility of the c-Src SH2-domain for binding is increased during mitosis.

S Bagrodia1, A P Laudano, D Shalloway.   

Abstract

The Src homology 2 (SH2) region is a noncatalytic domain of Src-family tyrosine kinases and other proteins which participants in inter- and intramolecular interactions of tyrosine-phosphorylated proteins. A synthetic peptide modeled on the c-Src carboxyl terminus, which contains phosphotyrosine at position 527, binds recombinant SH2 and the SH2-domain of c-Src which lacks phosphotyrosine 527. Unphosphorylated peptide does not bind detectably. Thus, the phosphorylated peptide is a specific probe for investigating SH2 accessibility. Since Src and other tyrosine kinases may participate in regulating events in mitosis, we used the SH2-binding probe to test the prediction that decreased tyrosine 527 phosphorylation would lead to increased accessibility of the c-Src SH2-domain during mitosis. Probe binding to overexpressed chicken c-Src was enhanced at least 6-fold during mitosis, indicating that the c-Src SH2-domain is more accessible in this part of the cell cycle. This suggests that there may be mitosis-specific interactions of the c-Src SH2-domain with cellular proteins in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511598

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Two mechanisms activate PTPalpha during mitosis.

Authors:  X M Zheng; D Shalloway
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

2.  The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.

Authors:  Danislav S Spassov; Frederick L Baehner; Ching Hang Wong; Stephen McDonough; Mark M Moasser
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

3.  Adhesion signaling by a novel mitotic substrate of src kinases.

Authors:  Ami S Bhatt; Hediye Erdjument-Bromage; Paul Tempst; Charles S Craik; Mark M Moasser
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

4.  Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.

Authors:  Byron J Aguilar; Yaxue Zhao; Huchen Zhou; Shouquan Huo; Yan-Hua Chen; Qun Lu
Journal:  Cancer Biol Ther       Date:  2019-03-08       Impact factor: 4.742

Review 5.  Targeting Cdc42 in cancer.

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Expert Opin Ther Targets       Date:  2013-08-19       Impact factor: 6.902

6.  A phosphotyrosine displacement mechanism for activation of Src by PTPalpha.

Authors:  X M Zheng; R J Resnick; D Shalloway
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.